As a university-based facility, clinicians and basic researchers at Moffitt collaborate to discover new therapies for hematologic malignancies. Research is ongoing in basic research laboratories, where scientists investigate how the disease originates, and in clinical investigations, where phase I and phase II studies are developed to introduce new drug therapies that can directly impact patient care.
Translational research brings new knowledge and treatments to the patient as quickly as possible.
All MDS patients are entered into the International Registry Database. A national registry for large granular lymphocytic leukemia also is based within the program. In addition to our own research programs, Moffitt participates in many regional and national cancer treatment studies. These sources should be used for informational purposes only. If you have a health-related problem, please consult a physician.